Peritoneal tuberculosis (PTB) is a paucibacillary disease with poor mycobacterial yield in ascitic fluid. The Xpert® MTB/RIF assay (Gene Xpert) is a new tool for the diagnosis of tuberculosis (TB) and has not yet been studied on peritoneal tissue. The present study aimed to investigate the yield of the Xpert® MTB/RIF assay on peritoneal tissue obtained at peritoneoscopy.
This is a retrospective study and the data were collected from hospital records. The patients who underwent peritoneoscopy along with Xpert® MTB/RIF assay on peritoneal tissue were included in this study. Those with proven PTB were considered as cases while those with other diagnoses as controls. Using the reference standard of TB diagnosis, sensitivity, specificity, and accuracy of Xpert® MTB/RIF assay were calculated.
Total of 36 patients was analyzed in this study: 28 as cases and eight as controls. Peritoneoscopy was carried out for diagnosis and biopsy. Histopathology in cases revealed caseating granulomas in 16 while 11 had non-caseating granulomas. Nine patients showed acid-fast bacillus positivity on peritoneal tissue. The most common finding on peritoneoscopy was tubercles with adhesions (n = 14, 50%), followed by tubercles only (n = 12, 42.9%). Xpert® MTB/RIF assay was positive in 17 (60.7%) patients with a sensitivity of 60.71%, specificity of 100%, and an accuracy of 69.44%. Two patients expressed rifampicin resistance.
Xpert® MTB/RIF assay on peritoneal tissue has fair sensitivity and excellent specificity. The multidrug resistance and the ability to provide results rapidly make it clinically useful.
Peritoneal tuberculosis (PTB) forms a significant proportion of abdominal tuberculosis population . Often, diagnosis is difficult in view of nonspecific symptoms and paucibacillary nature of the disease [2-3]. Ascitic fluid adenosine deaminase (ADA) can be used for the diagnosis as it has excellent sensitivity and specificity [4-6]. However, mycobacteriological analysis either by staining or culture remains the gold standard. Moreover, ADA cannot provide information on multidrug resistance (MDR) nature of bacteria . Furthermore, there is also a small but definite chance of false positive results with ADA. Xpert® MTB/RIF (Gene Xpert) assay is the latest addition in the clinician’s armamentarium for the diagnosis of tuberculosis. It uses nested polymerase chain reaction (PCR) technique with automated amplification and detects Mycobacterium tuberculosis and rifampicin resistance gene. The rifampicin resistance gene is an accurate surrogate marker for MDR tuberculosis (TB). Overall, Xpert® MTB/RIF assay has excellent sensitivity and specificity on sputum samples, especially which are acid-fast bacillus (AFB) positive on Zeihl-Neelsen stain. Therefore, Xpert® MTB/RIF is endorsed by the World Health Organization (WHO) for the diagnosis of pulmonary tuberculosis on sputum samples . Nowadays, Xpert® MTB/RIF assay is also increasingly applied to extrapulmonary samples. Recently published meta-analyses highlight this fact. However, studies included in these meta-analyses have few cases of peritoneal TB, and the tests were conducted only on ascitic fluid [8-9]. One study from India has used peritoneal tissue that was obtained by ultrasound-guided biopsy, and hence, was not sufficient to define the exact role of Xpert® MTB/RIF assay on peritoneal tissue . Therefore, the present study aimed to analyze the role of Xpert® MTB/RIF assay in the diagnosis of PTB on peritoneal tissue obtained by peritoneoscopy.
Materials & Methods
This retrospective case-control study deduced the efficacy of Xpert® MTB/RIF assay on peritoneal tissue. We retrieved the data of patients who underwent diagnostic laparoscopy (peritoneoscopy) for undiagnosed ascites due to the possibility of tuberculosis. Hospital records of patients at the Department of Gastroenterology and Gastrointestinal Surgery at G.B. Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India from December 2015-December 2017 were screened. All patients aged ≥18 years who underwent peritoneal biopsy along with Xpert® MTB/RIF assay were studied. Patients with incomplete data were excluded. Also, clinical features and parameters such as blood parameters and ascitic fluid analysis were noted. Additionally, reports of the tuberculin test, human immunodeficiency virus (HIV) test and visual findings of peritoneoscopy were recorded in all patients. The peritoneal biopsy was taken from visualized abnormal areas and subjected to histopathology and Xpert® MTB/RIF assay.
Xpert® MTB/RIF assay
The Xpert® MTB/RIF assay is a molecular technique, which uses nested real-time PCR method. The sample for this assay was collected in normal saline and processed within four hours. The Mycobacterium tuberculosis genes (MTB) and genes that confer rifampicin resistance (rpoB) are detected automatically by molecular probes. These are disposable cartridges that have the raw material, i.e., primers as well as molecular probes. It is a robust and rapid method making results available within two hours .
Definitions of cases and controls
Those patients who had proven PTB were considered as cases while those with other diagnoses were taken as controls. Definitions of cases and controls are described as follows:
Cases: All patients with a definite diagnosis of PTB and those who underwent Xpert® MTB/RIF assay on peritoneal tissue were taken as cases. The definite diagnosis of tuberculosis (reference standard) was considered if any of the following were present :
(1) Histopathology revealed AFB
(2) Caseating granulomas
(3) High clinical suspicion with non-caseating characteristic granuloma (multiple well-defined epithelioid granulomas with Langerhans’s giant cells) and response to antitubercular drugs (ATT)
Controls: All other patients who underwent peritoneoscopy but had a different diagnosis and were also subjected to Xpert® MTB/RIF assay testing on peritoneal tissue were taken as controls. All other diagnoses were confirmed by histopathology (for benign and malignant tumors). Endoscopic retrograde pancreatography with leak documentation was utilized for pancreatic ascites diagnosis. Chronic liver disease was diagnosed by ultrasonography, endoscopy, and/or liver biopsy.
All continuous data were expressed as mean, standard deviation, and median, while categorical data were expressed as percentages and proportions. Cases and controls parameters (continuous data) were compared using the Mann-Whitney U test and a p-value of less than 0.05 was taken as significant. Sensitivity, specificity, and accuracy were calculated according to the standard formulas. SPSS version 23 was used for statistical analysis.
A total of 43 patients underwent peritoneoscopy during the study. Tuberculosis was proven in 30 patients. Of these, Xpert® MTB/RIF assay was carried out in 28 patients who were included as cases for the present analysis. Of the remaining non-TB group, Xpert® MTB/RIF assay was conducted in eight patients that served as controls for comparison.
The male to female ratio in cases was 16:12. The mean age of the patients in the case group was 34.60±13 years. Of these, eight had underlying cirrhosis. The most common symptoms were anorexia, weight loss, and abdominal distension (n = 27, 96%), followed by abdominal pain in 26 (93%) patients. Tuberculin skin testing was positive in 19 (67.85%) patients at the cutoff of 10 mm. The ascitic fluid showed high protein (4.65±1.33 gm/dL) with low serum albumin ascitic albumin gradient (SAAG) (0.76±0.38 gm/dL) and high ADA value (70.37±18 IU/L). The blood and ascitic fluid parameters of patients are described in Table 1.
The most common finding on peritoneoscopy was tubercles with adhesions (n = 14, 50%) (Figure 1), followed by tubercles only (n = 12, 42.9%). Peritoneal thickening with tubercles and tubercles with cocoon was seen in one patient each. Histopathology revealed that AFB was positive in nine (32.1%) patients. A total of 16 (57.1%) patients had caseating granulomas, 11 (39.3%) had non-caseating granulomas (Figure 2) while one had non-specific inflammation but was AFB-positive. In addition, Xpert® MTB/RIF assay was found to be positive in 17 (60.7%) (Table 2), and rifampicin resistance was detected in two patients (7.1%).
The control group consisted of eight patients. Six patients had malignant ascites as peritoneal biopsy showed malignant deposits. One patient had pancreatic ascites while another had the chronic liver disease only. Peritoneoscopy revealed tubercles in five malignant ascites, while one showed omental caking only. One patient with pancreatic ascites had peritoneal thickening while another patient with chronic liver disease had normal peritoneum. All these patients exhibited negative results for Xpert® MTB/RIF assay.
Sensitivity, specificity, and accuracy of Xpert® MTB/RIF assay
In the present study, Xpert® MTB/RIF assay showed 60.71% (95% confidence interval (CI): 40.58-78.50) a sensitivity, 100% specificity (95% CI: 63.06-100), and accuracy of 69.44% (95% CI: 51.89-83.65).
All patients received ATT as per the national guidelines. Those who were Xpert® MTB/RIF assay-positive started ATT on day two, while those who are negatively received ATT after a median duration of seven days.
Tuberculosis is a major health concern in developing countries including India . The contribution of extrapulmonary tuberculosis to the total TB burden is on the rise comprising of PTB, which is difficult to diagnose due to its myriad symptoms and paucibacillary nature [2-3,13]. ADA is a satisfactory non-invasive test which is easily available nowadays and commonly used for the diagnosis of PTB owing to its sensitivity and specificity [4-6]. Despite this, a large number of patients undergo peritoneoscopy for diagnosis due to nonspecific symptoms and similarity to other illnesses . The Xpert® MTB/RIF assay was recently used for the diagnosis of pulmonary TB as well as for the detection of MDR TB and advocated by WHO for sputum testing . Its role in extrapulmonary tuberculosis is being studied increasingly. A few metanalyses have been published, but data on peritoneal tuberculosis are scarce [8-9]. Most studies published on PTB have used ascitic fluid for the Xpert® MTB/RIF assay. The yield of Xpert® MTB/RIF assay in the ascitic fluid was poor from 4%-28% [15-21]. Although this yield may be higher in HIV patients, only limited data are available . The results are as expected due to the paucibacillary nature of the disease and poor yield of smears and cultures in ascitic fluid . Hitherto, only one study has been published on the efficacy of Xpert® MTB/RIF assay on peritoneal tissue in PTB patients, which used ultrasound-guided peritoneal tissue . The current study documented a detailed account of 28 patients with the efficacy of Xpert® MTB/RIF assay on peritoneal tissue acquired by peritoneoscopy.
The present study had promising results. Also, we used robust reference diagnostic criteria that are clinically reliable and relevant. Using these as reference criteria, the sensitivity of Xpert® MTB/RIF assay in the current study was 60.71%, while specificity was 100%. While 100% specificity is not surprising as the Xpert® MTB/RIF assay is highly specific, as compared to a previously published study the assay exhibited high sensitivity in the current study (60.71% vs.19%) [7,10]. This phenomenon could be attributed to the abundant tissue obtained by peritoneoscopy. Gene Xpert also detected MDR TB in two patients (7.14%) in the current study which was less as compared to the other study published from Mumbai . Notably, we could diagnose tuberculosis and rifampicin resistance within four hours, which otherwise could have taken four days to four weeks. Moreover, ATT was started on day two in patients who were Xpert® MTB/RIF-positive as compared to those who were negative as they received it on day seven (median duration seven days). As shown previously, delayed diagnosis and the start of treatment worsens the prognosis and increases the mortality of PTB patients . Thus, Xpert® MTB/RIF assay is clinically vital and useful.
Nevertheless, the present study has some limitations. It is a retrospective study, and hence, we did not compare Xpert® MTB/RIF assay with respect to the culture owing to its variable yield in PTB. Also, the sample size of the current study was small. Additionally, a cost-effective analysis for Xpert® MTB/RIF assay could not be performed.
Xpert® MTB/RIF assay on peritoneal tissue obtained by peritoneoscopy has fair sensitivity and excellent specificity with a distinct advantage in the early diagnosis of MDR tuberculosis.
- Khuroo MS, Khuroo NS: Abdominal tuberculosis. In Tuberculosis. MM, Madkour (ed): Springer, Berlin, Heidelberg; 2004. 1:659-667. 10.1007/978-3-642-18937-1_37
- Sanai FM, Bzeizi KI: Systematic review: tuberculous peritonitis - presenting features, diagnostic strategies and treatment. Aliment Pharmacol Ther. 2005, 22:685-700. 10.1111/j.1365-2036.2005.02645.x
- Kapoor VK: Abdominal tuberculosis. Postgrad Med J. 1998, 74:459-467. 10.1136/pgmj.74.874.459
- Tao L, Ning H-J, Nie H-M, Guo X-Y, Qin S-Y, Jiang H-X: Diagnostic value of adenosine deaminase in ascites for tuberculosis ascites: a meta-analysis. Diagn Microbiol Infect Dis. 2014, 79:102-107. 10.1016/j.diagmicrobio.2013.12.010
- Shen Y, Wang T, Chen L, Yang T, Wan C, Hu QJ, Wen FQ: Diagnostic accuracy of adenosine deaminase for tuberculous peritonitis: a meta-analysis. Arch Med Sci. 2013, 9:601-607. 10.5114/aoms.2013.36904
- Riquelme A, Calvo M, Salech F, et al.: Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta-analysis. J Clin Gastroenterol. 2006, 40:705-710. 10.1097/00004836-200609000-00009
- Xpert mtb/rif implementation manual: technical and operational “how-to.” Geneva: World Health Organization. (2014). Accessed: March 4, 2019: https://apps.who.int/iris/bitstream/handle/10665/112469/9789241506700_eng.pdf.
- Maynard-Smith L, Larke N, Peters JA, Lawn SD: Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. BMC Infect Dis. 2014, 14:709. 10.1186/s12879-014-0709-7
- Penz E, Boffa J, Roberts DJ, Fisher D, Cooper R, Ronksley PE, James MT: Diagnostic accuracy of the Xpert® MTB/RIF assay for extra-pulmonary tuberculosis: a meta-analysis. Int J Tuberc Lung Dis. 2015, 19:278-284. 10.5588/ijtld.14.0262
- Bera C, Michael JS, Burad D, et al.: Tissue XpertTM MTB/Rif assay is of limited use in diagnosing peritoneal tuberculosis in patients with exudative ascites. Indian J Gastroenterol. 2015, 34:395-398. 10.1007/s12664-015-0599-7
- Logan VS: Anorectal tuberculosis. Proc R Soc Med. 1969, 62:1227-1230. Accessed: March 5,2019: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1815464/pdf/procrsmed00301-0045.pdf.
- Global Tuberculosis Report. (2014). Accessed: March 2, 2019: https://www.who.int/tb/publications/global_report/gtbr14_main_text.pdf.
- Prakasha SR, Suresh G, D’sa IP, Shetty SS, Kumar SG: Mapping the Pattern and Trends of Extrapulmonary Tuberculosis. J Glob Infect Dis. 2013, 5:54-59. 10.4103/0974-777X.112277
- Akgun Y: Intestinal and peritoneal tuberculosis: changing trends over 10 years and a review of 80 patients. Can J Surg. 2005, 48:131-136. Accessed: March 5, 2019: http://canjsurg.ca/wp-content/uploads/2014/03/48-2-131.pdf.
- Sajed AN, Akhtar R, Ahmad DI, et al.: Rapid detection of Mycobacterium tuberculosis and Rifampicin Resistance in extra pulmonary samples using Gene Xpert MTB/RIF assay. IOSR J Dental Med Sci. 2014, 13:50-53. 10.9790/0853-131145053
- Rufai S, Singh S, Singh A, Kumar P, Singh J, Vishal A: Performance of Xpert MTB/RIF on ascitic fluid samples for detection of abdominal tuberculosis. J Lab Physicians. 2017, 9:47-52. 10.4103/0974-2727.187927
- Ahmad R, Changeez M, Khan JS, et al.: Diagnostic accuracy of peritoneal fluid GeneXpert in the diagnosis of intestinal tuberculosis, keeping histopathology as the gold standard. Cureus. 2018, 10:3451-3454. 10.7759/cureus.3451
- Alvarez-Uria G, Azcona JM, Midde M, Naik PK, Reddy S, Reddy R: Rapid diagnosis of pulmonary and extrapulmonary tuberculosis in HIV-infected patients. Comparison of LED fluorescent microscopy and the GeneXpert MTB/RIF assay in a district hospital in India. Tuberc Res Treat. 2012, 2012:1-4. 10.1155/2012/932862
- Mittal M, Kumar R: Comparison of diagnostic yield of GeneXpert MTB/RIF assay and ZN (Ziehl-Neelsen) staining in serosal fluids from HIV and non-HIV patients with extra-pulmonary tuberculosis. Int J Res Med Sci. 2017, 5:2952-2955. 10.18203/2320-6012.ijrms20172967
- Nataraj G, Kanade S, Mehta P: Xpert® MTB/RIF for improved case detection of extra-pulmonary TB in a tertiary care setting in urban India. Int J Tuberc Lung Dis. 2016, 20:890-894. 10.5588/ijtld.15.0849
- Li Y, Pang Y, Zhang T, et al.: Rapid diagnosis of extrapulmonary tuberculosis with Xpert Mycobacterium tuberculosis/rifampicin assay. J Med Microbiol. 2017, 66:910-914. 10.1099/jmm.0.000522
- Sonambekar A, Desai D, Abraham P, et al.: Drug resistance in intestinal tuberculosis: a reason to worry?. JGH Open. 2017, 1:22-24. 10.1002/jgh3.12003
- Chow KM, Chow VCY, Hung LCT, Wong SM, Szeto CC: Tuberculous peritonitis-associated mortality Is high among patients waiting for the results of mycobacterial cultures of ascitic fluid samples. Clin Infect Dis. 2002, 35:409-413. 10.1086/341898
Tissue Xpert® MTB/RIF Assay in Peritoneal Tuberculosis: To be (Done) or Not to be (Done)
Ethics Statement and Conflict of Interest Disclosures
Human subjects: Consent was obtained by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Cite this article as:
Dahale A S, Puri A S, Kumar A, et al. (June 26, 2019) Tissue Xpert® MTB/RIF Assay in Peritoneal Tuberculosis: To be (Done) or Not to be (Done). Cureus 11(6): e5009. doi:10.7759/cureus.5009
Received by Cureus: May 31, 2019
Peer review began: June 05, 2019
Peer review concluded: June 14, 2019
Published: June 26, 2019
© Copyright 2019
Dahale et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.